SFX by Ex Libris Inc.

Title:	JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins
Source:	Embo Journal [0261-4189] Tsuruta, Fuminori yr:2004

Basic

Full text

Full text available via PubMed Central

Year:

Volume:

Issue:

Start Page:

Full text available via Wiley Online Library Full Collection 2019

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Meriin, A B. "Proteasome inhibitors activate stress kinases and induce Hsp72 Diverse effects on apoptosis." The Journal of biological chemistry 273.11 (1998): 6373-6379.
description	2.	Okuno, S. "The c-Jun N-terminal protein kinase signaling pathway mediates Bax activation and subsequent neuronal apoptosis through interaction with Bim after." The journal of neuroscience 24.36 (2004): 7879-87.
description	3.	Vielhaber, E. "Nuclear entry of the circadian regulator mPER1 is controlled by mammalian casein kinase I epsilon." Molecular and cellular biology 20.13 (2000): 4888-99.
description	4.	Ludwig, Fechner M. "Potent anti-inflammatory effects of low-dose proteasome inhibition in the vascular system." Journal of Molecular Medicine 87.8 (2009): 793-802.
description	5.	Drexler, H C A. "Activation of the cell death program by inhibition of proteasome function." Proceedings of the National Academy of Sciences of the United States of America 94.3 (1997): 855-860.
description	6.	Hideshima, T. "Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341." Blood 101.4 (2003): 1530-1534.
description	7.	Lei, K. "JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis." Proceedings of the National Academy of Sciences of the United States of America 100.5 (2003): 2432-7.
description	8.	Lee, D H H. "Proteasome inhibitors: valuable new tools for cell biologists." Trends in cell biology 8.10 (1998): 397-403.
description	9.	Jasper, H. "JNK extends life span and limits growth by antagonizing cellular and organism-wide responses to insulin signaling." Cell 121.1 (2005): 115-25.
description	10.	Fu, Y H H. "An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome." Science 291.5506 (2001): 1040-3.
description	11.	Archer, Simon N N. "A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference." Sleep 26.4 (2003): 413-5.
description	12.	Xu, Y. "Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome." Nature 434.7033 (2005): 640-4.
description	13.	Jones, C.R. R. "Familial advanced sleep-phase syndrome: A short-period circadian rhythm variant in humans." Nature medicine 5.9 (1999): 1062-1065.
description	14.	Jones, Samuel E. "Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms." Nature communications. 10.1: 343-11.
description	15.	Godinho, Sofia I H I. "The after-hours mutant reveals a role for Fbxl3 in determining mammalian circadian period." Science 316.5826 (2007): 897-900.
description	16.	Adams, J. "Proteasome inhibitors: A novel class of potent and effective antitumor agents." Cancer research 59.11 (1999): 2615-2622.
description	17.	Lopes, U. "p53-dependent induction of apoptosis by proteasome inhibitors." The Journal of biological chemistry 272.20 (1997): 12893-6.
description	18.	Richardson, M-V G. "Management of treatment-emergent peripheral neuropathy in multiple myeloma." Leukemia 26.4 (2011): 595-608.
description	19.	Meyer, S. "Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappa B activation." FEBS letters 413.2 (1997): 354-358.
description	20.	Mitsiades N, N. "The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications." Blood 101.6 (2003): 2377-80.